Dirk Groenewegen

• Translation of academic CGT / ATMP research into structured spin-out and exploitation strategies
• TRL-aligned development planning from preclinical proof-of-concept to clinical readiness
• IP strategy, licensing frameworks and value-preserving knowledge transfer
• License mediation and deal making
• Strategic governance, risk management and long-term sustainability of translational projects
• Support for non-dilutive funding applications (GO-Bio Next, European Innovation Council, national and EU programs)
• Support for private equity acquisition

Biotech entrepreneur and venture builder with more than 30 years of experience translating academic innovation into funded and clinically progressing life‑science companies. Founder and former CEO of Glycostem Therapeutics, advancing allogeneic NK cell therapies from licensed academic IP to clinical-stage development.

Extensive experience in European venture creation, IP strategy, licensing negotiations, valuation, fundraising and non‑dilutive financing. Trusted advisor to academic founders, startups, investors and public funding bodies, with deep domain expertise in cell & gene therapy, immuno‑oncology, regenerative medicine and advanced biologics.

Active European Innovation Council (EIC) Accelerator business coach and strategic advisor supporting companies from early concept through company formation, financing, clinical development and partnering.

PhD Microbiology, MSc Chemical Engineering, Hult Ashridge Business School, CELforPharma Product & Company Valuation

Rowing and Offshore Sailing